Tapewire

Nasdaq · USD

TYRA

Tyra Biosciences, Inc.

Export transactions ↓
Tapewire entity
4680
SEC CIK
0001863127
Parsed reports
203

Last 12 months

Inside the activity.

1 purchase rows · 14 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202507
Dec 202502
Jan 202602
Feb 202602
Mar 202601
Apr 202600
May 202600
Jun 202600
Jul 202600
Aug 202600
Sep 202610
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
September 15, 2026 Filed Sep 17, 2026 23:29 UTC
Harris ToddDirector · President and CEO
GrantCommon Stock 864 $9.13 $7,887.46
Disclosure

SEC source: 0001193125-26-394738 · ownership.xml · nonDerivative · entry 1

Harris Todd · CIK 0001711463 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,438,495

F1 · kind: These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan.

F2 · balance_after: Includes restricted stock units.

Read SEC document
September 15, 2026 Filed Sep 17, 2026 23:26 UTC
Rueb YuliyaVice President, Finance (PAO)
GrantCommon Stock 2,925 $9.13 $26,702.33
Disclosure

SEC source: 0001193125-26-394734 · ownership.xml · nonDerivative · entry 1

Rueb Yuliya · CIK 0002125370 · Vice President, Finance (PAO)

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,258

F1 · kind: These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan.

F2 · balance_after: Includes restricted stock units.

F3 · balance_after: The previously filed Form 4 overstated the number of securities beneficially owned by the Reporting Person in column 5, due to a clerical error, which has been corrected on this Form 4.

Read SEC document
September 15, 2026 Filed Sep 17, 2026 23:25 UTC
Fuhrman AlanChief Financial Officer
GrantCommon Stock 951 $9.13 $8,681.68
Disclosure

SEC source: 0001193125-26-394731 · ownership.xml · nonDerivative · entry 1

Fuhrman Alan · CIK 0001303521 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,115

F1 · kind: These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan.

F2 · balance_after: Includes restricted stock units.

Read SEC document
September 15, 2026 Filed Sep 17, 2026 20:31 UTC
RA CAPITAL MANAGEMENT, L.P.Director · 10% owner
RA Capital Healthcare Fund LPDirector · 10% owner
Kolchinsky PeterDirector · 10% owner
Shah Rajeev M.Director · 10% owner
PurchasePre-Funded Warrants (Right to Buy) · Derivative 9,078,529 $22.03 Strike: $0.00 $199,990,915.34
Disclosure

SEC source: 0001231919-26-001194 · form4-09172026_080941.xml · derivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 11,616,986

Underlying: Common Stock · 9,078,529 shares

Expires not disclosed

F1 · derivative.exercise_date: The Pre-Funded Warrants have no expiration date and are exercisable immediately. Notwithstanding the foregoing, the Reporting Persons shall not be entitled to exercise the Pre-Funded Warrants to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by the Reporting Persons, their affiliates and any persons who are members of a Section 13(d) group with the Reporting Persons or their affiliates to exceed 19.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise.

F1 · derivative.expiration_date: The Pre-Funded Warrants have no expiration date and are exercisable immediately. Notwithstanding the foregoing, the Reporting Persons shall not be entitled to exercise the Pre-Funded Warrants to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by the Reporting Persons, their affiliates and any persons who are members of a Section 13(d) group with the Reporting Persons or their affiliates to exceed 19.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise.

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

F3 · ownership.nature: Held directly by the Fund.

Read SEC document
September 09, 2026 Filed Sep 11, 2026 20:30 UTC
Verjee RehanDirector
PurchaseCommon Stock 971.8943 $20.58 $20,000.03
Disclosure

SEC source: 0001193125-26-389333 · ownership.xml · nonDerivative · entry 1

Verjee Rehan · CIK 0001880637 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 971.8943

F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $20.5550 to $20.6488. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

Read SEC document
May 28, 2026 Filed Jun 1, 2026 20:30 UTC GrantStock Option (Right to Buy) · Derivative 13,160 $0.00 Strike: $32.68 $0.00
Disclosure

SEC source: 0001193125-26-251532 · ownership.xml · derivative · entry 1

Rothenberg Stephen Michael · CIK 0002022747 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,160

Underlying: Common Stock · 13,160 shares

Expires 2036-05-27

F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 28, 2026, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

Read SEC document
May 28, 2026 Filed Jun 1, 2026 20:30 UTC
Simson JakeDirector
GrantStock Option (Right to Buy) · Derivative 13,160 $0.00 Strike: $32.68 $0.00
Disclosure

SEC source: 0001193125-26-251537 · ownership.xml · derivative · entry 1

Simson Jake · CIK 0001863094 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,160

Underlying: Common Stock · 13,160 shares

Expires 2036-05-27

F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 28, 2026, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

F2 · ownership.direct: Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), the RA Capital Nexus Fund, L.P. (the "Nexus Fund"), and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock.

Read SEC document
May 28, 2026 Filed Jun 1, 2026 21:45 UTC
RA CAPITAL MANAGEMENT, L.P.Director · 10% owner
RA Capital Healthcare Fund LPDirector · 10% owner
Kolchinsky PeterDirector · 10% owner
Shah Rajeev M.Director · 10% owner
GrantStock Option (Right to Buy) · Derivative 13,160 $0.00 Strike: $32.68 $0.00
Disclosure

SEC source: 0001231919-26-000590 · form4-06012026_090607.xml · derivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 13,160

Underlying: Common Stock · 13,160 shares

Expires 2036-05-27

F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 28, 2026, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to Jake Simson's continuous service to the Issuer through each vesting date.

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

F3 · ownership.nature: Under Mr. Simson's arrangement with the Adviser, Mr. Simson holds the option for the benefit of the Fund, the Nexus Fund, and the Account. Mr. Simson is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, the Nexus Fund, and the Account to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.

Read SEC document
May 28, 2026 Filed Jun 1, 2026 20:30 UTC
Verjee RehanDirector
GrantStock Option (Right to Buy) · Derivative 13,160 $0.00 Strike: $32.68 $0.00
Disclosure

SEC source: 0001193125-26-251539 · ownership.xml · derivative · entry 1

Verjee Rehan · CIK 0001880637 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,160

Underlying: Common Stock · 13,160 shares

Expires 2036-05-27

F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 28, 2026, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

Read SEC document
May 28, 2026 Filed Jun 1, 2026 20:30 UTC
Moran SusanDirector
GrantStock Option (Right to Buy) · Derivative 13,160 $0.00 Strike: $32.68 $0.00
Disclosure

SEC source: 0001193125-26-251538 · ownership.xml · derivative · entry 1

Moran Susan · CIK 0001835225 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,160

Underlying: Common Stock · 13,160 shares

Expires 2036-05-27

F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 28, 2026, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

Read SEC document
May 28, 2026 Filed Jun 1, 2026 20:30 UTC GrantStock Option (Right to Buy) · Derivative 13,160 $0.00 Strike: $32.68 $0.00
Disclosure

SEC source: 0001193125-26-251536 · ownership.xml · derivative · entry 1

Gulfo Adele M. · CIK 0001647102 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,160

Underlying: Common Stock · 13,160 shares

Expires 2036-05-27

F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 28, 2026, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

Read SEC document
May 28, 2026 Filed Jun 1, 2026 20:30 UTC GrantStock Option (Right to Buy) · Derivative 13,160 $0.00 Strike: $32.68 $0.00
Disclosure

SEC source: 0001193125-26-251534 · ownership.xml · derivative · entry 1

MORE ROBERT J · CIK 0001207792 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,160

Underlying: Common Stock · 13,160 shares

Expires 2036-05-27

F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 28, 2026, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

Read SEC document
May 05, 2026 Filed May 7, 2026 20:30 UTC
Warner Douglas JChief Medical Officer
GrantStock Option (Right to Buy) · Derivative 85,000 $0.00 Strike: $33.93 $0.00
Disclosure

SEC source: 0001193125-26-212116 · ownership.xml · derivative · entry 2

Warner Douglas J · CIK 0001941311 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Common Stock · 85,000 shares

Expires 2036-05-04

F3 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

Read SEC document
May 05, 2026 Filed May 7, 2026 20:30 UTC
Warner Douglas JChief Medical Officer
GrantCommon Stock 25,000 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-212116 · ownership.xml · nonDerivative · entry 1

Warner Douglas J · CIK 0001941311 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

F1 · shares: Represents restricted stock units ("RSUs") granted on May 5, 2026. 1/4 of the total number of RSUs granted vest on each of the first four anniversaries of May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

F2 · balance_after: Includes RSUs.

Read SEC document
May 05, 2026 Filed May 7, 2026 20:30 UTC
Fuhrman AlanChief Financial Officer
GrantStock Option (Right to Buy) · Derivative 67,000 $0.00 Strike: $33.93 $0.00
Disclosure

SEC source: 0001193125-26-212115 · ownership.xml · derivative · entry 2

Fuhrman Alan · CIK 0001303521 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,000

Underlying: Common Stock · 67,000 shares

Expires 2036-05-04

F3 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

Read SEC document
May 05, 2026 Filed May 7, 2026 20:30 UTC
Fuhrman AlanChief Financial Officer
GrantCommon Stock 20,000 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-212115 · ownership.xml · nonDerivative · entry 1

Fuhrman Alan · CIK 0001303521 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,164

F1 · shares: Represents restricted stock units ("RSUs") granted on May 5, 2026. 1/4 of the total number of RSUs granted vest on each of the first four anniversaries of May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

F2 · balance_after: Includes RSUs.

Read SEC document
May 05, 2026 Filed May 7, 2026 20:30 UTC
Harris ToddDirector · President and CEO
GrantStock Option (Right to Buy) · Derivative 265,000 $0.00 Strike: $33.93 $0.00
Disclosure

SEC source: 0001193125-26-212114 · ownership.xml · derivative · entry 2

Harris Todd · CIK 0001711463 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 265,000

Underlying: Common Stock · 265,000 shares

Expires 2036-05-04

F3 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

Read SEC document
May 05, 2026 Filed May 7, 2026 20:30 UTC
Harris ToddDirector · President and CEO
GrantCommon Stock 79,000 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-212114 · ownership.xml · nonDerivative · entry 1

Harris Todd · CIK 0001711463 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,437,631

F1 · shares: Represents restricted stock units ("RSUs") granted on May 5, 2026. 1/4 of the total number of RSUs granted vest on each of the first four anniversaries of May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

F2 · balance_after: Includes RSUs.

Read SEC document
May 05, 2026 Filed May 7, 2026 20:30 UTC
Rueb YuliyaVice President, Finance (PAO)
GrantStock Option (Right to Buy) · Derivative 28,000 $0.00 Strike: $33.93 $0.00
Disclosure

SEC source: 0001193125-26-212111 · ownership.xml · derivative · entry 2

Rueb Yuliya · CIK 0002125370 · Vice President, Finance (PAO)

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,000

Underlying: Common Stock · 28,000 shares

Expires 2036-05-04

F3 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

Read SEC document
May 05, 2026 Filed May 7, 2026 20:30 UTC
Rueb YuliyaVice President, Finance (PAO)
GrantCommon Stock 8,333 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-212111 · ownership.xml · nonDerivative · entry 1

Rueb Yuliya · CIK 0002125370 · Vice President, Finance (PAO)

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,354

F1 · shares: Represents restricted stock units ("RSUs") granted on May 5, 2026. 1/4 of the total number of RSUs granted vest on each of the first four anniversaries of May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

F2 · balance_after: Includes RSUs.

Read SEC document
May 05, 2026 Filed May 7, 2026 20:30 UTC
Ashar BhaveshChief Operating Officer
GrantStock Option (Right to Buy) · Derivative 50,295 $0.00 Strike: $33.93 $0.00
Disclosure

SEC source: 0001193125-26-212112 · ownership.xml · derivative · entry 2

Ashar Bhavesh · CIK 0001849740 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,295

Underlying: Common Stock · 50,295 shares

Expires 2036-05-04

F3 · derivative.exercise_date: 25% of the shares subject to the option shall vest on May 5, 2027, and 1/48th of the total number of shares subject to the option vest monthly thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

Read SEC document
May 05, 2026 Filed May 7, 2026 20:30 UTC
Ashar BhaveshChief Operating Officer
GrantCommon Stock 15,013 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-212112 · ownership.xml · nonDerivative · entry 1

Ashar Bhavesh · CIK 0001849740 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,013

F1 · shares: Represents restricted stock units ("RSUs") granted on May 5, 2026. 1/4 of the total number of RSUs granted vest on each of the first four anniversaries of May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

F2 · balance_after: Includes RSUs.

Read SEC document
April 16, 2026 Filed Apr 20, 2026 20:31 UTC GrantStock Option (Right to Buy) · Derivative 44,400 $0.00 Strike: $35.12 $0.00
Disclosure

SEC source: 0001193125-26-164090 · ownership.xml · derivative · entry 1

Dable Habib J · CIK 0001690773 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,400

Underlying: Common · 44,400 shares

Expires 2036-04-15

F1 · derivative.exercise_date: 1/36th of the total number of shares of common stock subject to the option vest monthly following April 16, 2026, the date of grant, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

Read SEC document
March 26, 2026 Filed Mar 27, 2026 20:44 UTC
KAPLAN GILLADirector
Exercise / conversionStock Option (Right to Buy) · Derivative 53,172 $0.00 Strike: $2.25 $0.00
Disclosure

SEC source: 0001193125-26-129239 · ownership.xml · derivative · entry 6

KAPLAN GILLA · CIK 0001247024 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 53,172 shares

Expires 2031-03-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Fully vested.

Read SEC document
March 26, 2026 Filed Mar 27, 2026 20:44 UTC
KAPLAN GILLADirector
Disposition to issuerCommon Stock 53,172 $37.75 $2,007,152.61
Disclosure

SEC source: 0001193125-26-129239 · ownership.xml · nonDerivative · entry 4

KAPLAN GILLA · CIK 0001247024 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,231

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.25 to $38.125. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
March 26, 2026 Filed Mar 27, 2026 20:44 UTC
KAPLAN GILLADirector
Exercise / conversionCommon Stock 53,172 $2.25 $119,637.00
Disclosure

SEC source: 0001193125-26-129239 · ownership.xml · nonDerivative · entry 3

KAPLAN GILLA · CIK 0001247024 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,403

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
March 25, 2026 Filed Mar 27, 2026 20:44 UTC
KAPLAN GILLADirector
Exercise / conversionStock Option (Right to Buy) · Derivative 14,295 $0.00 Strike: $2.25 $0.00
Disclosure

SEC source: 0001193125-26-129239 · ownership.xml · derivative · entry 5

KAPLAN GILLA · CIK 0001247024 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,172

Underlying: Common Stock · 14,295 shares

Expires 2031-03-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Fully vested.

Read SEC document
March 25, 2026 Filed Mar 27, 2026 20:44 UTC
KAPLAN GILLADirector
SaleCommon Stock 14,295 $36.97 $528,506.16
Disclosure

SEC source: 0001193125-26-129239 · ownership.xml · nonDerivative · entry 2

KAPLAN GILLA · CIK 0001247024 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,231

F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.95 to $37.11. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
March 25, 2026 Filed Mar 27, 2026 20:44 UTC
KAPLAN GILLADirector
Exercise / conversionCommon Stock 14,295 $2.25 $32,163.75
Disclosure

SEC source: 0001193125-26-129239 · ownership.xml · nonDerivative · entry 1

KAPLAN GILLA · CIK 0001247024 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,526

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
March 13, 2026 Filed Mar 17, 2026 20:59 UTC
Fuhrman AlanChief Financial Officer
GrantCommon Stock 1,376 $9.13 $12,561.50
Disclosure

SEC source: 0001193125-26-111100 · ownership.xml · nonDerivative · entry 1

Fuhrman Alan · CIK 0001303521 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,164

F1 · kind: These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan.

Read SEC document
March 13, 2026 Filed Mar 17, 2026 20:54 UTC
Harris ToddDirector · President and CEO
GrantCommon Stock 1,463 $9.13 $13,355.73
Disclosure

SEC source: 0001193125-26-111083 · ownership.xml · nonDerivative · entry 1

Harris Todd · CIK 0001711463 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,358,631

F1 · kind: These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan.

Read SEC document
February 12, 2026 Filed Feb 13, 2026 21:30 UTC
Bensen DanielChief Discovery Officer
SaleCommon Stock 5,872 $33.37 $195,928.68
Disclosure

SEC source: 0001193125-26-051534 · ownership.xml · nonDerivative · entry 2

Bensen Daniel · CIK 0001880946 · Chief Discovery Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 146,981

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $32.98 to $33.85. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

Read SEC document
February 12, 2026 Filed Feb 13, 2026 21:30 UTC
Bensen DanielChief Discovery Officer
SaleCommon Stock 2,128 $31.50 $67,035.83
Disclosure

SEC source: 0001193125-26-051534 · ownership.xml · nonDerivative · entry 1

Bensen Daniel · CIK 0001880946 · Chief Discovery Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 152,853

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $31.02 to $31.75. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

Read SEC document
January 12, 2026 Filed Jan 20, 2026 21:30 UTC
Bensen DanielChief Discovery Officer
SaleCommon Stock 1,017 $29.08 $29,575.17
Disclosure

SEC source: 0001193125-26-016651 · ownership.xml · nonDerivative · entry 2

Bensen Daniel · CIK 0001880946 · Chief Discovery Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 154,981

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $28.9131 to $29.23. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

Read SEC document
January 12, 2026 Filed Jan 20, 2026 21:30 UTC
Bensen DanielChief Discovery Officer
SaleCommon Stock 6,983 $28.44 $198,610.49
Disclosure

SEC source: 0001193125-26-016651 · ownership.xml · nonDerivative · entry 1

Bensen Daniel · CIK 0001880946 · Chief Discovery Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 155,998

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $27.9083 to $28.84. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

Read SEC document
December 19, 2025 Filed Dec 20, 2025 02:00 UTC SaleCommon Stock 10,000 $25.00 $250,000.00
Disclosure

SEC source: 0001193125-25-327254 · ownership.xml · nonDerivative · entry 1

MORE ROBERT J · CIK 0001207792 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 3,823,425

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Alta Partners NextGen Fund II, L.P. ("APNG II") on June 26, 2025.

F2 · ownership.nature: These securities are held directly by APNG II. The Reporting Person is a managing director of the general partner of APNG II and shares voting and investment control with respect to the shares held by APNG II. The Reporting Person disclaims beneficial ownership of all shares held by APNG II, except to the extent of his pecuniary interest therein.

Read SEC document
December 12, 2025 Filed Dec 16, 2025 21:30 UTC
Bensen DanielChief Discovery Officer
SaleCommon Stock 8,000 $22.64 $181,159.20
Disclosure

SEC source: 0001193125-25-320941 · ownership.xml · nonDerivative · entry 1

Bensen Daniel · CIK 0001880946 · Chief Discovery Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 162,981

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $22.06 to $23.03. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

Read SEC document
December 01, 2025 Filed Dec 1, 2025 23:17 UTC
Ashar BhaveshChief Operating Officer
GrantStock Option (Right to Buy) · Derivative 300,000 $0.00 Strike: $20.81 $0.00
Disclosure

SEC source: 0001193125-25-304160 · ownership.xml · derivative · entry 1

Ashar Bhavesh · CIK 0001849740 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 300,000

Underlying: Common Stock · 300,000 shares

Expires 2035-11-30

F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on December 1, 2026, and 1/48th of the total number of shares subject to the option vest monthly thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

Read SEC document
November 21, 2025 Filed Nov 25, 2025 22:00 UTC SaleCommon Stock 246,871 $20.25 $5,000,026.49
Disclosure

SEC source: 0001193125-25-297551 · ownership.xml · nonDerivative · entry 1

MORE ROBERT J · CIK 0001207792 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 3,833,425

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Alta Partners NextGen Fund II, L.P. ("APNG II") on June 26, 2025.

F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $20.25 to $21.24. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F3 · ownership.nature: These securities are held directly by APNG II. The Reporting Person is a managing director of the general partner of APNG II and shares voting and investment control with respect to the shares held by APNG II. The Reporting Person disclaims beneficial ownership of all shares held by APNG II, except to the extent of his pecuniary interest therein.

Read SEC document
November 19, 2025 Filed Nov 20, 2025 00:30 UTC
Bensen DanielChief Operating Officer
SaleCommon Stock 49,956 $16.32 $815,296.91
Disclosure

SEC source: 0001193125-25-288529 · ownership.xml · nonDerivative · entry 2

Bensen Daniel · CIK 0001880946 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 170,981

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.04 to $16.68. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

Read SEC document
November 18, 2025 Filed Nov 20, 2025 00:30 UTC
Bensen DanielChief Operating Officer
SaleCommon Stock 75,633 $16.07 $1,215,626.52
Disclosure

SEC source: 0001193125-25-288529 · ownership.xml · nonDerivative · entry 1

Bensen Daniel · CIK 0001880946 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 220,937

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.00 to $16.24. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

Read SEC document
November 17, 2025 Filed Nov 18, 2025 00:03 UTC
Bensen DanielChief Operating Officer
SaleCommon Stock 1,500 $17.07 $25,606.95
Disclosure

SEC source: 0001193125-25-284935 · ownership.xml · nonDerivative · entry 4

Bensen Daniel · CIK 0001880946 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 296,570

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

F5 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $17.06 to $17.09. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

Read SEC document
November 17, 2025 Filed Nov 18, 2025 00:03 UTC
Bensen DanielChief Operating Officer
SaleCommon Stock 18,572 $16.11 $299,191.21
Disclosure

SEC source: 0001193125-25-284935 · ownership.xml · nonDerivative · entry 3

Bensen Daniel · CIK 0001880946 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 298,070

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

F4 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.00 to $17.00. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

Read SEC document
November 14, 2025 Filed Nov 18, 2025 00:03 UTC
Bensen DanielChief Operating Officer
SaleCommon Stock 110,228 $16.02 $1,765,488.81
Disclosure

SEC source: 0001193125-25-284935 · ownership.xml · nonDerivative · entry 2

Bensen Daniel · CIK 0001880946 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 316,642

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.00 to $16.13. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

Read SEC document
November 13, 2025 Filed Nov 18, 2025 00:03 UTC
Bensen DanielChief Operating Officer
SaleCommon Stock 1,111 $16.00 $17,780.00
Disclosure

SEC source: 0001193125-25-284935 · ownership.xml · nonDerivative · entry 1

Bensen Daniel · CIK 0001880946 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 426,870

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.00 to $16.02. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

Read SEC document
September 15, 2025 Filed Sep 17, 2025 21:57 UTC
Fuhrman AlanChief Financial Officer
GrantCommon Stock 701 $9.13 $6,399.43
Disclosure

SEC source: 0001193125-25-206439 · ownership.xml · nonDerivative · entry 1

Fuhrman Alan · CIK 0001303521 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,788

F1 · kind: These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan.

Read SEC document
August 07, 2025 Filed Aug 7, 2025 20:38 UTC
Warner Douglas JChief Medical Officer
GrantStock Option (Right to Buy) · Derivative 200,000 $0.00 Strike: $10.75 $0.00
Disclosure

SEC source: 0000950170-25-105132 · ownership.xml · derivative · entry 1

Warner Douglas J · CIK 0001941311 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2035-08-06

F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on August 7, 2026, and 1/36th of the remaining number of shares subject to the option vest monthly thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

Read SEC document
August 07, 2025 Filed Aug 7, 2025 20:43 UTC
Fuhrman AlanChief Financial Officer
GrantStock Option (Right to Buy) · Derivative 170,000 $0.00 Strike: $10.75 $0.00
Disclosure

SEC source: 0000950170-25-105153 · ownership.xml · derivative · entry 1

Fuhrman Alan · CIK 0001303521 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 170,000

Underlying: Common Stock · 170,000 shares

Expires 2035-08-06

F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following August 7, 2025, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

Read SEC document
August 07, 2025 Filed Aug 7, 2025 20:36 UTC
Harris ToddDirector · President and CEO
GrantStock Option (Right to Buy) · Derivative 570,000 $0.00 Strike: $10.75 $0.00
Disclosure

SEC source: 0000950170-25-105128 · ownership.xml · derivative · entry 1

Harris Todd · CIK 0001711463 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 570,000

Underlying: Common Stock · 570,000 shares

Expires 2035-08-06

F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following August 7, 2025, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

Read SEC document
August 07, 2025 Filed Aug 7, 2025 20:40 UTC
Bensen DanielChief Operating Officer
GrantStock Option (Right to Buy) · Derivative 170,000 $0.00 Strike: $10.75 $0.00
Disclosure

SEC source: 0000950170-25-105140 · ownership.xml · derivative · entry 1

Bensen Daniel · CIK 0001880946 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 170,000

Underlying: Common Stock · 170,000 shares

Expires 2035-08-06

F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following August 7, 2025, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.